US07725L1026 - ADR
BEIGENE LTD-ADR
NASDAQ:BGNE (4/24/2024, 9:15:06 AM)
143.32
+4.33 (+3.12%)
Beigene Ltd is a KY-based company operating in Biotechnology industry. BeiGene, Ltd. is a global biotechnology company. The firm is focused on developing and commercializing oncology medicines to improve treatment outcomes and expand access for patients worldwide. The firm has discovered and developed three approved medicines including, BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; tislelizumab, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of PARP1 and PARP2. BRUKINSA is a second-generation small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) designed to maximize BTK occupancy and minimize off-target binding effects. The company has obtained approvals to market BRUKINSA in the United States, China, the European Union, the United Kingdom, Canada and Australia. The firm has in-licensed the rights to distribute 13 approved medicines for the China market.
BEIGENE LTD-ADR
94 Solaris Avenue,, Camana Bay
George Town BEIJING KY1-1108
P: 13459494123
CEO: John V. Oyler
Employees: 9212
Website: https://www.beigene.com/
Here you can normally see the latest stock twits on BGNE, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: